Global HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market 2024-2028

Global HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market 2024-2028

The HER2 (human epidermal growth factor receptor 2) inhibitors market is forecasted to grow by USD 11066.53 mn during 2023-2028, accelerating at a CAGR of 9.94% during the forecast period. The report on the HER2 (human epidermal growth factor receptor 2) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high prevalence of breast cancer and gastric cancer, advancements in R&D, and growing awareness about breast cancer.

Technavio's HER2 (human epidermal growth factor receptor 2) inhibitors market is segmented as below:

By Product

• Monotherapy
• Combination therapy

By Distribution Channel

• Retail pharmacies
• Hospital pharmacies
• Online pharmacies

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the patient assistance programs as one of the prime reasons driving the HER2 (human epidermal growth factor receptor 2) inhibitors market growth during the next few years. Also, introduction of new diagnostics for breast cancer and strategic alliances will lead to sizable demand in the market.

The report on the HER2 (human epidermal growth factor receptor 2) inhibitors market covers the following areas:

• HER2 (human epidermal growth factor receptor 2) inhibitors market sizing
• HER2 (human epidermal growth factor receptor 2) inhibitors market forecast
• HER2 (human epidermal growth factor receptor 2) inhibitors market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading HER2 (human epidermal growth factor receptor 2) inhibitors market vendors that include Amgen Inc., AryoGen Pharmed, AstraZeneca Plc, Biocon Ltd., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Dr Reddys Laboratories Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Intas Pharmaceuticals Ltd., JSC BIOCAD, MacroGenics Inc., Merck KGaA, Novartis AG, Pfizer Inc., Puma Biotechnology Inc., Samsung Biologics Co. Ltd., Shanghai Henlius Biotech Inc., Viatris Inc., and Celltrion Healthcare Co. Ltd.. Also, the HER2 (human epidermal growth factor receptor 2) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth